---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042382"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T13:43:17.911727+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences Q2 net loss $8.2M, cash $25.1M; advances cytisinicline NDA submission H1 2024

## Summary
- Net loss of $8.2M in Q2 2023; cash, equivalents and restricted cash $25.1M as of June 30, 2023.
- Positive Phase 3 ORCA-3 trial confirmed cytisinicline efficacy/safety for smoking cessation in 792 smokers.
- Phase 2 ORCA-V1: cytisinicline increased odds of quitting vaping 2.6x vs placebo (31.8% vs 15.1%).
- Plan to submit New Drug Application for cytisinicline in first half of 2024.
- Raised $16.5M in registered direct offering; refinanced $16.6M SVB debt with maturity to Dec 2024.

## SEC filing metadata
- accession: 0000950170-23-042382
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000095017023042382/0000950170-23-042382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000095017023042382/achv-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042382
- JSON: https://secwatch.observer/filing/0000950170-23-042382.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042382.txt

## Key facts
- Earnings Releases
  ACHIEVE LIFE SCIENCES, INC. reported second quarter of 2023 results: revenue $25.1 million, net income $8.2 million.
  - Period: second quarter of 2023
  - Revenue: $25.1 million
  - Net income: $8.2 million
  - Result: reported results
  source text: terminated in connection with the new contingent convertible debt agreement. Financial Results As of June 30, 2023, the company’s cash, cash equivalents, and restricted cash was $25.1 million. Total operating expenses for the three and six months ended June 30, 2023 were $7.7 million and $16.3 million, respectively. Total net loss for the three and six months ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000095017023042382/0000950170-23-042382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.